Reply to: "Prediction of HBsAg loss after cessation of entecavir therapy"

Rex Wan-Hin Hui; Lung-Yi Mak; Man-Fung Yuen

doi:10.1016/j.jhep.2024.10.041

Reply to: "Prediction of HBsAg loss after cessation of entecavir therapy"

J Hepatol. 2024 Nov 6:S0168-8278(24)02656-4. doi: 10.1016/j.jhep.2024.10.041. Online ahead of print.

Authors

Rex Wan-Hin Hui¹, Lung-Yi Mak², Man-Fung Yuen³

Affiliations

¹ Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR.
² Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR.
³ Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR. Electronic address: [email protected].

PMID: 39515423
DOI: 10.1016/j.jhep.2024.10.041

No abstract available

Keywords: Alanine aminotransferase; Entecavir; Finite; Flare; Functional cure; Hepatitis B surface antigen; Hepatitis B virus; Liver cirrhosis; Nucleos(t)ide analogue.

Publication types

Letter